Advertisement

A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene–receptor antagonist

      Abstract

      Background: The cysteinyl leukotrienes are important mediators of bronchial asthma. The clinical effect of montelukast, a potent cysteinyl leukotriene–receptor antagonist, was investigated in a randomized, placebo-controlled, multicenter, parallel-group, dose-ranging study.
      Methods: After a 3-week, single-blind, placebo run-in period, 343 asthmatic patients (FEV1 40% to 80% of the predicted value with an improvement in FEV1 of at least 15% [absolute value] after receiving inhaled β-agonists on at least two occasions) were randomly assigned to one of six treatment groups: placebo; 10, 100, or 200 mg once daily montelukast in the evening; or 10 or 50 mg twice daily montelukast for a 6-week, double-blind treatment period followed by a 1-week placebo washout period. All patients used inhaled, short-acting β-agonists as needed.
      Results: All montelukast doses caused similar and significant differences compared with placebo in asthma control endpoints. The least-square mean difference between pooled montelukast groups and placebo in the percentage change from baseline in morning FEV1 (10.30%; 95% CI: 5.56 to 15.04), as-needed β-agonist use (–0.98 puffs; 95% CI: –1.53 to –0.44), morning peak expiratory flow rate (18.80 L/min; 95% CI: 8.62 to 28.98), physicians’ and patients’ global evaluations, and asthma-specific quality-of-life scores were all significant (p ≤ 0.050). The incidence of adverse experiences was not dose related and was similar between placebo and montelukast treatment.
      Conclusion: Montelukast caused a significant improvement in chronic asthma at an oral, once daily evening dose as low as 10 mg. (J Allergy Clin Immunol 1998;102:50-6.)

      Keywords

      Abbreviations:

      ANOVA: (Analysis of variance), CI: (Confidence interval), CysLT: (Cysteinyl leukotriene receptor), LS: (Least squares), PEFR: (Peak expiratory flow rate)
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Allergy and Clinical Immunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dahlen SE
        • Hedquist P
        • Hammerstrom S
        • Samuelsson B
        Leukotrienes are potent constrictors of human bronchi.
        Nature. 1980; 288: 484-486
        • Marom Z
        • Shelhamer JH
        • Bach MK
        • Morton DR
        • Kaliner M
        Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro.
        Am Rev Respir Dis. 1982; 126: 449-451
        • Woodward DF
        • Wichmann BF
        • Gill CA
        • Wassermann MA
        The effect of synthetic leukotrienes on tracheal microvascular permeability.
        Prostaglandins. 1983; 25: 131-142
        • Drazen JM
        • Austen KF
        Leukotrienes and airway responses.
        Am Rev Respir Dis. 1987; 136: 985-998
        • Labat C
        • Ortiz JL
        • Norel X
        • Gorenne I
        • Verley J
        • Abrams TS
        • et al.
        A second cysteinyl leukotriene receptor in human lung.
        J Pharmacol Exp Ther. 1992; 263: 800-805
        • Jones TR
        • Labelle M
        • Belley M
        • Champion E
        • Charette L
        • Evans J
        • Ford-Hutchinson AW
        • et al.
        Pharmacology of montelukast sodium (SINGULAIR), a potent and selective leukotriene D4-receptor antagonist.
        Can J Physiol Pharmacol. 1995; 73: 191-201
        • DeLepeleire I
        • Reiss TF
        • Rochette F
        • Botto A
        • Zhang J
        • Kundu S
        • et al.
        Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma.
        Clin Pharmacol Ther. 1997; 61: 83-92
        • Crapo RO
        • Hankinson JL
        • Irvin C
        Standardization of spirometry.
        Am J Respir Crit Care Med. 1995; 152: 1107-1136
        • Santanello NC
        • Barber BL
        • Reiss TF
        • Friedman BS
        • Juniper EF
        • Zhang J
        Measurement characteristics of two asthma symptom diary scales for use in clinical trials.
        Eur Respir J. 1997; 10: 646-651
        • Juniper EF
        • Guyatt GH
        • Epstein RS
        • Ferrie PJ
        • Jaeschke R
        • Hiller TK
        Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials.
        Thorax. 1992; 47: 76-83
        • Tukey JW
        • Ciminera JL
        • Heyse JF
        Testing the statistical certainty of a response to increasing doses of a drug.
        Biometrics. 1985; 41: 295-301
        • Chervinsky P
        • van As A
        • Bronsky EA
        • Dockhorn R
        • Noonan M
        • LaForce C
        • et al.
        Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma.
        J Allergy Clin Immunol. 1994; 94: 676-683
        • Toogood JH
        High-dose inhaled steroid therapy for asthma.
        J Allergy Clin Immunol. 1989; 83: 528-536
        • Spector SL
        • Smith LJ
        • Glass M
        • the ACCOLATE Asthma Trialists Group
        Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma.
        Am J Respir Crit Care Med. 1994; 150: 618-623
        • Impens N
        • Reiss TF
        • Teahan JA
        • Desmet M
        • Rossing TH
        • Shingo S
        • et al.
        Acute bronchodilation with an intravenously administered leukotriene D4 antagonist, MK-679.
        Am Rev Respir Dis. 1993; 147: 1442-1446
        • Gaddy NJ
        • Margolskee DJ
        • Bush RK
        • Williams VC
        • Busse WW
        Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma.
        Am Rev Respir Dis. 1992; 146: 358-363
        • Hui KP
        • Barnes NC
        Lung function improvement in asthma with a cysteinyl leukotriene receptor antagonist.
        Lancet. 1991; 337: 1062-1063
        • U.S. Department of Health and Human Services
        National Asthma Education Program, Expert Panel Report. Guidelines for the diagnosis and management of asthma.
        : National Heart, Lung, and Blood Institute, Bethesda (MD)1992 (Publication No. 91–3042)
        • Juniper EF
        • Guyatt GH
        • Willan A
        • Griffith LE
        Determining a minimal important change in a disease-specific quality of life questionnaire.
        J Clin Epidemiol. 1994; 47: 81-87
        • U.S. Department of Health and Human Services
        National Heart, Lung, and Blood Institute/World Health Organization Workshop Report. Global initiative for asthma: global strategy for asthma management and prevention.
        : National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda (MD)1995 (Publication No. 95–3659)
        • Taylor DR
        • Sears MR
        • Herbison GP
        • Flannery EM
        • Print CG
        • Lake DC
        • et al.
        Regular inhaled β-agonist in asthma: effects on exacerbations and lung function.
        Thorax. 1993; 48: 134-138
        • Bousquet JP
        • Chanez JY
        • Lacoste G
        • Barnéon G
        • Ghavanian N
        • Exander I
        • et al.
        Eosinophilic inflammation in asthma.
        N Engl J Med. 1990; 323: 1033-1039
        • Wickremasingh RG
        • Khan MA
        • Hoffbrand AV
        Do leukotrienes play a role in the regulation of proliferation of normal and leukemic hemopoietic cells?.
        Prostaglandins Leukot Essent Fatty Acids. 1993; 48: 123-126
        • Laitinen L
        • Laitinen A
        • Haahtela T
        • Vilkka V
        • Spur BW
        • Lee TH
        Leukotriene E4 and granulocytic infiltration into asthmatic airways.
        Lancet. 1993; 341: 989-990